Cantor Fitzgerald Weighs in on GPCR FY2026 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Structure Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($1.99) per share for the year. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share.

Other research analysts have also recently issued research reports about the stock. HC Wainwright cut their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. Finally, William Blair initiated coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has an average rating of "Buy" and a consensus price target of $76.50.

Structure Therapeutics Stock Down 2.2%

NASDAQ:GPCR traded down $0.50 during trading hours on Wednesday, reaching $22.22. The company had a trading volume of 713,948 shares, compared to its average volume of 856,829. The stock has a 50-day moving average of $22.49 and a two-hundred day moving average of $24.76. Structure Therapeutics has a one year low of $13.22 and a one year high of $53.45. The firm has a market capitalization of $1.27 billion, a PE ratio of -30.03 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03).

Institutional Trading of Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GPCR. Deep Track Capital LP boosted its stake in Structure Therapeutics by 129.4% in the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $46,782,000 after buying an additional 575,000 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth $13,560,000. Marshall Wace LLP boosted its position in shares of Structure Therapeutics by 339.6% in the fourth quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after acquiring an additional 450,531 shares during the period. Finally, Foresite Capital Management VI LLC acquired a new position in shares of Structure Therapeutics in the fourth quarter valued at about $11,390,000. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.